Pharmacogenetic Dosing of Warfarin

Completed

Phase 3 Results N/A

Summary of Purpose

Purpose: Warfarin is now the most commonly used oral anticoagulant. This drug has inter-individual variability due to the genetic polymorphisms in the warfarin metabolizing enzyme, CYP2C9 and warfarin target, VKORC1. The investigators' team developed a pharmacogenetic dosing algorithm which can predict patients required warfarin dose, thus could prevent warfarin induced warfarin adverse events. ...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 16 February 2014.

1 Sep 2009 9 Feb 2014 1 Dec 2013 1 Dec 2013 1 Feb 2014 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

Not available